GENE ONLINE|News &
Opinion
Blog

2021-11-18| M&A

Following Two Years of Promising RNAi Collab, Novo Nordisk Decides to Acquire Dicerna for $3.3 Billion

by Rajaneesh K. Gopinath
Share To
In November 2019, Dicerna Pharmaceuticals entered a strategic collaboration with Danish multinational pharma, Novo Nordisk to discover and develop novel therapies for liver-related cardio-metabolic diseases using its GalXC technology. The deal aimed to explore more than 30 liver cell targets and develop clinical candidates for a multitude of disorders including chronic liver disease, non-alcoholic steatohepatitis (NASH), type 2 diabetes, obesity, and rare diseases. 

Almost exactly two years later, Novo Nordisk has decided to completely acquire the Lexington, MA-based biotech in an all-cash deal for $38.25 per share that amounts to a total of $3.3 billion in equity value. This represents a premium of almost 80% to Dicerna's closing price on Wednesday. The M&A deal is expected to close in the fourth quarter of 2021, said the company in a statement. It also expects to initiate clinical development with the first target next year.

GO Prime with only $1.49 now

LATEST
Blueprint Medicines Gathers Up To $1.25 Billion in Loans and Investments for Research and Development
2022-07-01
FDA Halts Sanofi’s $3.7B Multiple Sclerosis Investment
2022-07-01
Takeda Reveals Positive Data on Takhzyro at EAACI
2022-07-01
Bon Natural Life Limited Announces Change to Board Composition
2022-06-30
These Pharma Companies Are Laying Off Employees Due to Restructuring
2022-06-30
US Bio-Entrepreneur Program Launches in the UK
2022-06-30
ReCode Therapeutics’ Secures an Extra $120 Million To Support Its Drug Delivery Platform
2022-06-30
EVENT
2022-07-27
BIO Asia–Taiwan 2022
Online and on-side
2022-08-03
BIOPLUS-INTERPHEX KOREA
Seoul
2022-09-09
ESMO 2022 Exhibition
Online and on-side
2022-09-21
CSCO Educational Book 2022
Xiamen
2022-09-21
RESI Boston
Boston
2022-09-26
Human Gene Therapy Conference
Australia
Scroll to Top